Managing HPV: A New Era in Patient Care: Screening and Management of Abnormal Results

Learning Objectives

• Correctly apply national guidelines for the initiation, interval, and cessation of cervical cancer screening to patients in your clinical practice.
• Correctly differentiate between appropriate and inappropriate use of HPV DNA testing.
• Correctly apply the recommended interval for follow up and management of repeat HPV DNA  testing in the primary screening of women age 30 and older in your clinical practice. 
• Correctly apply recommended guidelines for management of abnormal cervical cytology results.
• Identify recommended management of abnormal cervical cytology results for pregnant, postmenopausal, immunosuppressed, and adolescent women.

Accreditation Information

Physicians: The Association of Reproductive Health Professionals is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. ARHP designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Nurses: This educational activity has been approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for 1 contact hours, including 1 pharmacology hours. Credit can be applied toward the nursing continuing requirements of most professional organizations and State Boards of Nursing.

Others: A certificate of attendance will be issued indicating that this activity is accredited for 1 hour of AMA PRA Category 1 Credit^TM.

Sponsoring Information

This program is sponsored by the Association of Reproductive Health Professionals and Planned Parenthood Federation of America^®.

Funding Information

The Managing HPV program is funded through educational grants from a collaboration of companies including GlaxoSmithKline, Graceway Pharmaceuticals, Merck and Co. Inc., Roche Pharmaceuticals, and QIAGEN.

Disclosure Information

All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.

• Barbara J.B. Clark, MPAS, PA-C: Speaker for Ortho Women’s Health and Urology and Wyeth Pharmaceuticals
• Don Downing, R.Ph: has no affiliations to disclose
• Francisco Garcia, MD, MPH: has no affiliations to disclose
• Sherri Sheinfeld Gorin, PhD: has no affiliations to disclose
• Richard Guido, MD : Conducted research for Graceway Pharmaceuticals and Tigress Pharmaceuticals; speaker for Merck and Co., Inc.; consultant for GlaxoSmithKline
• Julie Hibben, LMSW, CPSI: has no affiliations to disclose
• Mary Rubin, RNC, PhD, CRNP: Speaker for Digene Corporation and Merck and Co., Inc.
• Marie Savard, MD: Speaker for Digene Corporation and GlaxoSmithKline
• Anafidelia Tavares , MD has no affiliations to disclose
• Maria Trent, MD: Speaker for Merck and Co., Inc. Medical Forums
• Thomas C. Wright, MD: Consultant for Glaxo Smith Kline, Merck and Co., Inc. and Roche Molecular Systems, Inc.

ARHP Staff/Consultant Disclosures

• Vanessa Cullins, MD: Receives grants and research support from Digene Corporation, Graceway Pharmaceuticals, Merck and Co., Inc., and Ortho Women’s Health, Urology Wyeth Pharmaceuticals; consultant for Merck and Co., Inc.; speaker for Ortho Women’s Health and Urology
• Shama Alam, MScPH, Julie Altier, Shelby Everitt, Katy Quissell, MPH, Diane Shannon, MD, MPH, Wayne Shields, Amy Swann, MA, and Sandy Worthington MSN, CNM, RNC have no affiliations to disclose